---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Care management intervention strategies"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Care management intervention strategies. Topics: Management of darovasertib plus crizotinib toxicities through dose holds, dose reductions, dietary counseling, and expert-center linkage; Crizotinib label: patient counseling on hepatotoxicity, bradycardia, and blood pressure medications; Crizotinib label: patient counseling on vision disorders, drug interactions, and photosensitivity; Pharmacist-led interventions for oral anticancer therapy: systematic review and meta-analysis of 27 studies; 10 further topics. 14 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Management of darovasertib plus crizotinib toxicities through dose holds, dose reductions, dietary counseling, and expert-center linkage

> “Meredith McKean, MD, MPH, the director of the Melanoma and Skin Cancer Research Program at Sarah Cannon Research Institute in Nashville, Tennessee, highlighted that the short half-life of darovasertib/crizotinib typically makes brief holds and dose reductions sufficient to keep patients on therapy when paired with dietary counseling.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

<a id="topic-2.2.2.4-2"></a>

### Crizotinib label: patient counseling on hepatotoxicity, bradycardia, and blood pressure medications

> “Inform patients to immediately report symptoms of hepatotoxicity [see Warnings and Precautions (5.1)].”
> “Advise patients to report any symptoms of bradycardia and to inform their healthcare provider about the use of any heart or blood pressure medications [see Warnings and Precautions (5.4)].”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.2.2.4-3"></a>

### Crizotinib label: patient counseling on vision disorders, drug interactions, and photosensitivity

> “Inform patients of the potential risk of severe visual loss and to immediately contact their healthcare provider if they develop severe visual loss.”
> “Inform patients that visual changes such as perceived flashes of light, blurry vision, light sensitivity, and floaters are commonly reported adverse reactions and may occur while driving or operating machinery.”
> “Inform patients to avoid grapefruit or grapefruit juice while taking XALKORI.”
> “Advise patients to inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products [see Drug Interactions (7)].”
> “Advise patients to avoid prolonged sun exposure and to use sunscreen or protective clothing during treatment with XALKORI [see Adverse Reactions (6.1)].”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.2.2.4-4"></a>

### Pharmacist-led interventions for oral anticancer therapy: systematic review and meta-analysis of 27 studies

> “A total of 27 studies evaluating pharmacist-led interventions in patients receiving oral anticancer therapy were identified through systematic searches, including randomized controlled trials, non-randomized controlled trials, and cohort studies.”
> “The study identified 11 pharmacist interventions distributed across four main domains, namely patient education and behavioral support, symptom and toxicity management, medication therapy management, and healthcare access support.”
> “The meta-analysis revealed that pharmacist interventions tend to improve medication adherence and treatment persistence.”
> “However, the impact on clinical endpoints and the incidence of drug-related problems remained heterogeneous.”

Source: [Liu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42152179/)

<a id="topic-2.2.2.4-5"></a>

### Tebentafusp: expert recommendations on liver value monitoring and the two major toxicities

> “The safety profile of tebentafusp is manageable and includes two major pathologies: cytokine release syndrome (CRS) and skin-related events.”
> “The monitoring of liver values is crucial, as patients may experience an increase in transaminases, which can even manifest as tumour lysis syndrome.”

Source: [Hassel et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/37595494/)

<a id="topic-2.2.2.4-6"></a>

### Tebentafusp: symptomatic management of cytokine release in a 2026 systematic review

> “Symptomatic management with antipyretics, glucocorticoids, and intravenous fluids is strongly recommended to mitigate these effects.”

Source: [Lanzafame et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12984979/)

<a id="topic-2.2.2.4-7"></a>

### Tebentafusp: structured adverse event monitoring in community oncology practice

> “In our practice, we utilize the EMR to embed drug-specific laboratory tests and AE monitoring guidance at appropriate time intervals in treatment order sets.”
> “This structured AE monitoring and management guidance is critical to ensuring that a patient safely remains on treatment and derives clinical benefit for as long as possible.”

Source: [Resnick (2026)](https://www.ajmc.com/view/considerations-for-use-of-tebentafusp-a-bite-approved-for-rare-high-risk-uveal-melanoma)

<a id="topic-2.2.2.4-8"></a>

### Tebentafusp: management of skin reactions

> “Most cutaneous reactions are mild and can be effectively managed with emollients, topical corticosteroids, and antihistamines, while permanent discontinuation of therapy is uncommon.”

Source: [Koumprentziotis et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13664555/)

<a id="topic-2.2.2.4-9"></a>

### Immune checkpoint inhibitors: management of immune-related adverse events by grade

> “The management of immune-related adverse events depends on their severity: in mild cases (grade 1), therapy can be continued with simple monitoring; in moderate cases (grade 2), therapy is temporarily suspended and oral corticosteroids are administered; in severe cases (grade 3 or 4), treatment is discontinued and high-dose corticosteroids are used, possibly with additional immunosuppressants such as infliximab for refractory colitis or mycophenolate for hepatitis.”

Source: [Lanzafame et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12984979/)

<a id="topic-2.2.2.4-10"></a>

### Response assessment with RECIST, tumor growth rate, and circulating tumor DNA

> “Treatment efficacy assessment includes response evaluation criteria in solid tumours (RECIST), tumour growth rate (TGR) analysis, and ctDNA dynamics.”

Source: [Rodrigues et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40628555/)

> “Faculty agreed on one clear use case for ctDNA: distinguishing true progression from the radiographic pseudoprogression and waxing-and-waning patterns characteristic of tebentafusp response.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

<a id="topic-2.2.2.4-11"></a>

### Early palliative and supportive care in the guideline

> “Early integration of palliative care is internationally recommended to facilitate the transition from curative to palliative care and to individualise the intensity of care for patients with cancer.”
> “It may include psychological support, nutrition and palliative care support.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.4-12"></a>

### Surveillance for metastasis after treatment of the primary tumor at reference centers

> “Prognostication and surveillance should be led by a specialist MTB with UM expertise in ophthalmology, liver imaging, surgery, medical oncology and supportive care.”
> “Surveillance strategies should be managed at reference centres [III, A].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.4-13"></a>

### Risk-based surveillance imaging after treatment of the primary tumor: North American Delphi consensus

> “Intermediate-risk patients should be screened for metastatic disease with a minimum frequency of every 3–6 months for 5 years, thereafter annually for at least 10 years from diagnosis.”
> “High-risk patients should be screened for metastatic disease with a minimum frequency of every 3–6 months for years 1–5 and every 6–12 months for years 6–10.”
> “In high-risk patients, the use of contrast-enhanced MRI abdomen is preferred over CT abdomen for surveillance of metastatic uveal melanoma.”
> “Although there was agreement that low-risk patients warrant surveillance, no consensus was reached on the optimal approach for this group.”

Source: [Alban et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12784650/)

<a id="topic-2.2.2.4-14"></a>

### Patient education and patient organizations

> “Patient education should be evidence-based, verifiable and accessible to enable patients to seek the right information to improve communication with their health care team.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
